NEWTON,
Mass., April 1, 2024 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today announced that the
Company granted an aggregate of 79,800 restricted stock units
(RSUs) to five newly-hired employees. These RSU awards were granted
as of March 31, 2024 (the "Grant
Date") pursuant to the Company's 2022 Inducement Stock Incentive
Plan, as amended, as inducements material to the new employees
entering into employment with Karyopharm in accordance with Nasdaq
Listing Rule 5635(c)(4).
Each RSU award will vest over three years, with 33 1/3% of the
shares underlying the RSU award vesting on each of the three
consecutive anniversaries of the Grant Date. The vesting of each
RSU award is subject to the employee's continued service as an
employee of, or other service provider to, Karyopharm through the
applicable vesting dates. In addition, each RSU award will be
immediately exercisable in full if, on or prior to the first
anniversary of the consummation of a "change in control event," the
employee's employment is terminated for "good reason" by the
employee or terminated without "cause" by Karyopharm (as such terms
are defined in the applicable RSU agreement).
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a
commercial-stage pharmaceutical company pioneering novel cancer
therapies. Since its founding, Karyopharm has been an industry
leader in oral Selective Inhibitor of Nuclear Export (SINE)
compound technology, which was developed to address a fundamental
mechanism of oncogenesis: nuclear export dysregulation.
Karyopharm's lead SINE compound and first-in-class, oral exportin 1
(XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and
marketed by the Company in three oncology indications and has
received regulatory approvals in various indications in a growing
number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline
targeting multiple high unmet need cancer indications, including in
multiple myeloma, endometrial cancer, myelodysplastic neoplasms and
myelofibrosis. For more information about our people, science and
pipeline, please visit www.karyopharm.com, and follow us on Twitter
at @Karyopharm and LinkedIn.
XPOVIO® and NEXPOVIO® are registered
trademarks of Karyopharm Therapeutics Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302104524.html
SOURCE Karyopharm Therapeutics Inc.